Type your tag names separated by a space and hit enter

PITUITARY HORMONE HYPERSECRETION SYNDROMES

PITUITARY HORMONE HYPERSECRETION SYNDROMES is a topic covered in the Harrison's Manual of Medicine.

To view the entire topic, please or purchase a subscription.

Harrison’s Manual of Medicine 19th edition provides 600+ internal medicine topics in a rapid-access format. Download Harrison’s App to iPhone, iPad, and Android smartphone and tablet. Explore these free sample topics:

Harrison’s Manual of Medicine - App + Web

-- The first section of this topic is shown below --

HYPERPROLACTINEMIA

Prolactin is unique among the pituitary hormones in that the predominant central control mechanism is inhibitory, reflecting dopamine-mediated suppression of PRL release. Prolactin acts to induce and maintain lactation and decrease reproductive function and drive (via suppression of gonadotropin-releasing hormone [GnRH], gonadotropins, and gonadal steroidogenesis).

Etiology

Physiologic elevation of PRL occurs in pregnancy and lactation. Otherwise, PRL-secreting pituitary adenomas (prolactinomas) are the most common cause of PRL levels >100 μg/L. Less pronounced hyperprolactinemia is commonly caused by medications (risperidone, chlorpromazine, perphenazine, haloperidol, metoclopramide, opiates, H2 antagonists, amitriptyline, selective serotonin reuptake inhibitors [SSRIs], verapamil, estrogens), pituitary stalk damage (tumors, lymphocytic hypophysitis, granulomas, trauma, irradiation), primary hypothyroidism, or renal failure. Nipple stimulation may also cause acute PRL increases.

Clinical Features

In women, amenorrhea, galactorrhea, and infertility are the hallmarks of hyperprolactinemia. In men, symptoms of hypogonadism (Chap. 174) or mass effects are the usual presenting symptoms, and galactorrhea is rare.

Diagnosis

Fasting, morning PRL levels should be measured; when clinical suspicion is high, measurement of levels on several different occasions may be required. If hyperprolactinemia is present, nonneoplastic causes should be excluded (e.g., pregnancy test, hypothyroidism, medications).

Treatment

If the pt is taking a medication that is known to cause hyperprolactinemia, the drug should be withdrawn, if possible. A pituitary MRI should be performed if the underlying cause of PRL elevation is unknown. Resection of hypothalamic or sellar mass lesions can reverse hyperprolactinemia due to stalk compression. Medical therapy with a dopamine agonist is indicated in microprolactinomas for control of symptomatic galactorrhea, for restoration of gonadal function, or when fertility is desired. Alternatively, estrogen replacement may be indicated if fertility is not desired, but tumor size should be carefully monitored. Dopamine agonist therapy for macroprolactinomas generally results in both adenoma shrinkage and reduction of PRL levels. Cabergoline (initial dose 0.5 mg a week, usual dose 0.5–1 mg twice a week) and bromocriptine (initial dose 0.625–1.25 mg qhs, usual dose 2.5 PO three times a day) are the two most frequently used dopamine agonists. Cabergoline is the more effective and better-tolerated drug. These medications should initially be taken at bedtime with food, followed by gradual dose increases, to reduce the side effects of nausea and postural hypotension. Other side effects include constipation, nasal stuffiness, dry mouth, nightmares, insomnia, or vertigo; decreasing the dose usually alleviates these symptoms. Dopamine agonists may also precipitate or worsen underlying psychiatric conditions. Cardiac echocardiography is prudent before starting cabergoline therapy as there has been concern about an association with valvular heart disease. In pts with microadenomas successfully treated (normal PRL, full tumors shrinkage), therapy may be withdrawn after 2 years, followed by careful monitoring for tumor recurrence. Spontaneous remission of microadenomas, presumably caused by infarction, occurs in some pts. Surgical debulking may be required for macroprolactinomas that do not adequately respond to medical therapy.

Women with microprolactinomas who become pregnant should discontinue dopaminergic therapy, as the risk for significant tumor growth during pregnancy is low. In those with macroprolactinomas, visual field testing should be performed at each trimester. A pituitary MRI should be performed if severe headache and/or visual defects occur.

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Loscalzo, Joseph, et al., editors. "PITUITARY HORMONE HYPERSECRETION SYNDROMES." Harrison's Manual of Medicine, 19th ed., McGraw Hill Inc., 2017. harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623412/all/PITUITARY_HORMONE_HYPERSECRETION_SYNDROMES.
PITUITARY HORMONE HYPERSECRETION SYNDROMES. In: Loscalzo J, Jameson JL, Longo DL, et al, eds. Harrison's Manual of Medicine. 19th ed. McGraw Hill Inc.; 2017. https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623412/all/PITUITARY_HORMONE_HYPERSECRETION_SYNDROMES. Accessed April 21, 2019.
PITUITARY HORMONE HYPERSECRETION SYNDROMES. (2017). In Loscalzo, J., Jameson, J. L., Longo, D. L., Hauser, S. L., Fauci, A. S., & Kasper, D. L. (Eds.), Harrison's Manual of Medicine. Available from https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623412/all/PITUITARY_HORMONE_HYPERSECRETION_SYNDROMES
PITUITARY HORMONE HYPERSECRETION SYNDROMES [Internet]. In: Loscalzo J, Jameson JL, Longo DL, Hauser SL, Fauci AS, Kasper DL, editors. Harrison's Manual of Medicine. McGraw Hill Inc.; 2017. [cited 2019 April 21]. Available from: https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623412/all/PITUITARY_HORMONE_HYPERSECRETION_SYNDROMES.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - PITUITARY HORMONE HYPERSECRETION SYNDROMES ID - 623412 ED - Loscalzo,Joseph, ED - Jameson,J Larry, ED - Longo,Dan L, ED - Hauser,Stephen L, ED - Fauci,Anthony S, ED - Kasper,Dennis L, BT - Harrison's Manual of Medicine UR - https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623412/all/PITUITARY_HORMONE_HYPERSECRETION_SYNDROMES PB - McGraw Hill Inc. ET - 19 DB - Harrison's Manual of Medicine DP - Unbound Medicine ER -